KYTX – kyverna therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $13.00 price target on the stock.
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $16.00 price target on the stock.
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Form 4 Kyverna Therapeutics, For: Oct 21 Filed by: Aktar Mert
Form 3 Kyverna Therapeutics, For: Oct 21 Filed by: Aktar Mert
Form 8-K Kyverna Therapeutics, For: Oct 20
Form SC 13G Kyverna Therapeutics, Filed by: JPMORGAN CHASE & CO
Form 4 Kyverna Therapeutics, For: Sep 16 Filed by: Biddle Warner Weston
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.